HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in <i>RAS</i>-wt advanced colorectal cancer (aCRC).
Jenny F. Seligmann(University of Leeds), Andrew B. Nixon(Duke University), Kouros Owzar(Duke University), Herbert I. Hurwitz(Duke Medical Center), Faye Elliott(University of Leeds), Philip Quirke(University of Leeds), Michel Seymour(University of Leeds), Bart Jacobs, Ace J. Hatch(Duke Medical Center), Alexander B. Sibley(Duke University), Chen Jiang, Susan D. Richman(University of Leeds)
Cited by 1
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k